The Lp-PLA2 test measures lipoprotein-associated phospholipase A2, an enzyme that travels on lipoprotein particles and reflects vascular inflammation. At Longevity Benchmark, we separate what clinical trial research supports from laboratory marketing so readers can evaluate whether elective panel add-ons justify their cost. Higher levels correlate with cardiovascular risk. However, direct clinical trials showed that lowering this enzyme does not reduce heart attacks or deaths.
The Verdict
What Lp-PLA2 Measures And What It Does Not Settle
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an enzyme that circulates in blood and functions inside arterial tissue. The American College of Cardiology describes the investigational drug darapladib as a direct lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor that reduces Lp-PLA2 activity in plasma and atherosclerotic plaques. That single sentence summarizes the biological domain of this enzyme. It sits within plaques.
Commercial laboratories often market this assay as the PLAC test. Patients frequently discover it as an optional add-on to cardiovascular screening panels. The fundamental problem with the test involves clinical utility. An elevated reading shows that the enzyme is present within vascular lesions. Yet measuring it does not establish whether intervening against the enzyme alters disease progression. No intervention on this page has been shown to act on the number, so a result leaves the reader with nothing to change.
The Trial That Tested Whether Lowering It Helps
The hypothesis that suppressing Lp-PLA2 would prevent cardiovascular events was formally tested in the SOLID-TIMI 52 trial. The full investigation was titled Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52. The study enrolled 13,026 patients. Participants joined within 30 days of an acute coronary syndrome (ACS). Every participant also presented with at least one additional risk factor, including age 60 or older, prior myocardial infarction (MI), chronic kidney disease, diabetes requiring medication, or polyvascular disease.
Follow-up continued for a median of 2.5 years. Investigators tracked coronary heart disease death, myocardial infarction, or urgent coronary revascularization for myocardial ischaemia. The primary outcome occurred in 16.3% of the darapladib group and 15.6% of the placebo group. The resulting p-value was 0.93. The American College of Cardiology summary concluded that among patients with recent ACS, darapladib was not associated with a reduction in adverse cardiovascular events compared with placebo. The report also stated that Lp-PLA2 does not appear to be a favorable therapeutic target to reduce adverse events.
Marker Versus Target
A statistical association between an enzyme and disease risk does not establish a valid therapeutic target. This distinction separates a useful risk marker from a clinical intervention. Lp-PLA2 activity tracks cardiovascular risk across population studies. However, the SOLID-TIMI 52 findings showed that lowering enzyme activity does not change clinical outcomes. These two findings do not contradict one another.
SOLID-TIMI 52 tested whether lowering the enzyme changes events, and it did not. That is a result about the intervention, not about whether the enzyme tracks risk. The association stands. The attempt to treat it failed. Clinicians evaluate whether an abnormal lab result leads to a validated treatment. With Lp-PLA2, no intervention has proven that reducing the number prevents clinical events.
| Question | What Lp-PLA2 Answers | What It Does Not Answer |
|---|---|---|
| Is vascular inflammation present? | Elevated activity indicates enzyme presence in plasma and atherosclerotic plaques. | It does not reveal the underlying driver of that inflammation. |
| Does the reading track cardiovascular risk? | Yes, higher levels correlate with increased risk in observational studies. | It does not establish a causal relationship that responds to enzyme suppression. |
| Will lowering this number reduce heart attacks? | No clinical trial supports this assumption. | Lowering the enzyme failed to reduce coronary heart disease death, MI, or urgent revascularization in 13,026 patients. |
| Does the test provide a clear therapeutic next step? | It offers no approved therapeutic target. | It does not indicate a specific drug or lifestyle intervention proven to improve outcomes. |
The Second Trial, And Why Two Nulls Matter More Than One
A second phase III trial confirmed that direct inhibition of Lp-PLA2 does not improve clinical outcomes. The STABILITY trial evaluated darapladib in patients with stable coronary heart disease. In both studies, darapladib failed to reduce the risk of major coronary events compared with placebo. The trial evidence demonstrated consistent failure across both acute and stable clinical settings.
Tolerability created further problems. Darapladib was associated with significantly higher rates of drug discontinuation compared with placebo. Participants reported distinct adverse effects, including diarrhoea and malodorous faeces, urine, and skin. A single negative study can leave lingering questions about dosing or timing. Two large trials found no benefit from lowering the enzyme as an actionable intervention. When a drug fails across both acute and stable cohorts while causing distinct side effects, clinical development stops.
Why No Cutoff Appears On This Page
This page does not publish a diagnostic cutoff or normal reference range for the Lp-PLA2 test. Commercial diagnostic companies use two different testing methods that cannot be directly compared. One method measures enzymatic activity, while the other measures mass concentration. The activity assay and the mass assay do not share a single scale.
Laboratories establish their own internal reference intervals based on the specific equipment and methodology deployed. Standardization across different test kits does not exist. Consequently, applying a single threshold to every laboratory report produces inaccurate assessments. For a broader explanation of reference interval discrepancies, see our guide to normal versus optimal ranges. The reference range printed on your personal laboratory paperwork is the only standard that applies to your result. A clinician must interpret that specific figure in the context of the testing laboratory.
What The Guidelines Did With It
Cardiovascular prevention guidelines initially recognized Lp-PLA2 testing before removing the marker from subsequent updates. Lp-PLA2 testing was included in 2010 American College of Cardiology and American Heart Association guidance on cardiovascular risk assessment in asymptomatic patients. The marker was subsequently absent from the 2019 joint guidelines published by those same organizations.
Major prevention guidelines prioritize tests that directly inform patient management. The guidelines do not say why. What is on the record is the sequence: present in 2010, absent in 2019, with the two darapladib trials published in between. Modern prevention frameworks focus resources on markers with proven interventions. The test lost its place in routine cardiovascular workups.
Who Should Not Buy This Test
Most individuals paying for preventive blood work should decline an elective Lp-PLA2 test. Clinical panels should deliver actionable results rather than uninterpretable numbers. We identify three common situations where purchasing this assay misdirects resources:
- Patients who have not yet tested primary lipid markers. Anyone who has not established baseline levels for ApoB or Lp(a) should prioritize those tests. Both markers provide direct targets with established treatment protocols.
- Individuals seeking actionable lifestyle or medication changes. Lowering Lp-PLA2 has not been shown to reduce cardiovascular events. A high or low number does not provide a proven clinical intervention.
- Anyone looking for a standard systemic inflammation screen. For general vascular inflammation assessment, standard clinical practice relies on high-sensitivity C-reactive protein. Review our guide to hs-CRP, read about high CRP levels, or explore broader inflammation blood tests instead.
What Would Change This Assessment
Our editorial evaluation of the Lp-PLA2 test would change if future clinical trials demonstrated clear therapeutic utility. Three distinct developments would force a re-evaluation of this marker:
- A successful randomized intervention trial. Investigators would need to demonstrate that an intervention targeting Lp-PLA2 reduces heart attacks, strokes, or cardiovascular mortality.
- Guideline restoration by major cardiology bodies. Consensus panels at the American College of Cardiology and American Heart Association would need to restore the test to routine prevention guidance.
- Proven risk reclassification beyond standard panels. Researchers must prove that adding the enzyme changes clinical management and reclassifies cardiovascular risk beyond established markers like ApoB and Lp(a).
If Lp-PLA2 is on a panel you are being quoted for, ask what the result would change, and spend the money on ApoB and Lp(a) first if either is still unmeasured.
Frequently Asked Questions
What is the Lp-PLA2 test?
The Lp-PLA2 test measures lipoprotein-associated phospholipase A2, an enzyme measured in plasma and in atherosclerotic plaques. The American College of Cardiology notes that this enzyme resides in plasma and atherosclerotic lesions. Commercial laboratories frequently offer this blood test to assess vascular inflammation, often branding it as the PLAC test. While higher concentrations correlate with cardiovascular risk in observational studies, clinical trials have demonstrated that directly inhibiting the enzyme does not reduce cardiovascular events. Consequently, the test functions as a descriptive marker of arterial inflammation rather than a measurement with an actionable treatment target.
What is a normal Lp-PLA2 level?
This page does not publish a normal reference range or diagnostic cutoff for the Lp-PLA2 test. Testing companies use two entirely different laboratory methods: an activity assay and a mass assay. These two assays do not share a common measurement scale, so their numerical outputs cannot be compared directly. Each testing laboratory establishes its own reference interval depending on the specific equipment and reagents used. Because no single universal cutoff exists, patients must refer exclusively to the reference interval printed on their individual laboratory report. A licensed healthcare provider should interpret those specific numbers alongside a comprehensive cardiovascular evaluation.
Is the Lp-PLA2 test the same as the PLAC test?
Yes, the PLAC test is simply a registered commercial brand name for the Lp-PLA2 test. Both terms describe the laboratory measurement of lipoprotein-associated phospholipase A2. Specialized diagnostic companies and private longevity clinics frequently market the PLAC test as an advanced vascular inflammation screen. Some versions of the test quantify the mass concentration of the enzyme in blood, while other versions calculate its enzymatic activity level. Regardless of the marketing name on the laboratory requisition form, both assays measure the same biological enzyme and share the same clinical limitations regarding actionability.
Is Lp-PLA2 better than hs-CRP?
Lp-PLA2 is not better than hs-CRP for clinical prevention. High-sensitivity C-reactive protein (hs-CRP) is the inflammation marker that sits on standard clinical panels. In contrast, Lp-PLA2 travels on lipoprotein particles and reflects enzymatic activity in vascular plaques. However, hs-CRP has extensive guideline support and established clinical protocols for interpreting cardiovascular risk. Our guides to hs-CRP and hs-CRP vs glycans outline how clinicians evaluate chronic inflammation. Because clinical trials showed that lowering Lp-PLA2 does not prevent cardiovascular events, hs-CRP remains the standard inflammation test in routine practice.
Can you lower Lp-PLA2?
This page carries no evidence-based lifestyle or pharmacological intervention to lower Lp-PLA2. In clinical research, a direct pharmaceutical inhibitor named darapladib successfully reduced enzyme activity in plasma and atherosclerotic plaques. However, in the SOLID-TIMI 52 trial involving 13,026 patients, that reduction failed to lower rates of cardiovascular death, myocardial infarction, or urgent coronary revascularization. A second phase III study confirmed that direct inhibition did not reduce major coronary events. Furthermore, darapladib caused significant rates of drug discontinuation and adverse effects including diarrhoea and malodorous skin, urine, and faeces. Lowering the number has not been shown to improve health outcomes.
Do cardiology guidelines recommend Lp-PLA2 testing?
Major cardiology guidelines do not currently recommend routine Lp-PLA2 testing. The test was included in 2010 guidance from the American College of Cardiology and American Heart Association regarding cardiovascular risk assessment in asymptomatic adults. It appeared in that 2010 guidance and it is absent from the 2019 joint guidelines. No class of recommendation for it appears on this page, and the guideline documents do not state a reason for the change. Today, cardiovascular guideline bodies emphasize proven lipid targets and validated risk calculators over elective vascular enzyme tests that lack actionable treatment pathways.
Should I get Lp-PLA2 tested if my hs-CRP is normal?
A normal hs-CRP result does not justify ordering an Lp-PLA2 test. The case made for Lp-PLA2 is that it reads inflammation inside the artery wall rather than inflammation across the body, but clinical trial evidence fails to support acting on that reading. When researchers directly lowered Lp-PLA2 activity in large patient populations, clinical cardiovascular outcomes did not improve. Someone whose hs-CRP already sits inside their lab's range is in the group with the least to gain from a second inflammation number, because no intervention on this page has been shown to act on it. ApoB and Lp(a) are the two markers on this site that do carry an action. Which of them belongs on a panel is a conversation for a clinician.
Is Lp-PLA2 worth adding to a longevity panel?
For most individuals, adding an Lp-PLA2 test to an elective longevity panel is not worth the expense. Commercial wellness panels add novel biomarkers to look comprehensive, and clinical value depends on actionability. An Lp-PLA2 result provides descriptive data about vascular enzyme presence without offering a validated intervention to lower cardiovascular risk. Prioritize proven foundational markers such as ApoB and Lp(a) before considering secondary vascular enzymes. A test is only as valuable as the clinical decisions it informs, and current evidence shows that targeting Lp-PLA2 does not prevent cardiovascular events.